Morgan Stanley upgraded Gilead Sciences, Inc. GILD from Equal-weight to Overweight Monday and raised its price target from $100 to $104.
Analyst Matthew Harrison felt that price fears were exaggerated. Analysts at Bank of America and Deutsche Bank predicted a possible price war following the decision of Express Scripts to chose AbbVie Inc ABBV as its exclusive supplier of hepatitis C treatments.
Harrison saw an improved risk-to-reward ratio now that shares have declined and felt the company can maintain a 75 percent market share even with the AbbVie price discounts.
Gilead Sciences, Inc. recently traded at $96.86, up 3.27 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.